Additional endpoints included glycaemic outcomes and safety profiles
Feuilloley MG (2019) Acne and stress: impact of catecholamines on Cutibacterium acnes
Key considerations include: Watching for signs of pancreatitis or gallbladder disease Looking at the patients overall health and medical history Changing the dosage or stopping treatment if side effects happen In patients with a history of gallbladder disease or cholecystectomy, the decision to start or keep using GLP-1 receptor agonist therapy should be made on a case-by-case basis
Its a far more elegant approach than starting high and dealing with a cascade of unwanted variables
doi: 10.1016/j.phymed.2024.156314 180 QiMYHeYHChengYFangQMaRYZhouSJet al
Do not start, stop, or change any GLP-1 program without talking to your healthcare provider, especially if you are pregnant, breastfeeding, taking other medications, or have a personal or family history of medullary thyroid carcinoma or MEN-2.